What is the Purpose of this Study?
The purpose of this study is to determine whether using less intense radiation therapy and chemotherapy (chemoradiation) after trans-oral robotic surgery (TORS) will be as effective in treating HPV-associated oropharyngeal cancer as standard treatment while also reducing side effects. Patients will receive 3, 4, or 5 weeks of treatment depending on the extent of the disease at the time of surgery and the presence or absence of tumor tissue in the blood after the completion of surgery, instead of the standard 6-6.5 weeks of treatment. The chemotherapy drugs used in this study (cisplatin, or carboplatin and paclitaxel, if applicable) are approved by the U.S. Food and Drug Administration (FDA).
Eligibility
Not Available
Where can I participate?
- CS Cancer Tarzana
- CS Cancer at Beverly Hills
- CS Cancer at Cedars-Sinai Medical Center
- CS Cancer at The Angeles Clinic and Research Institute
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer
What is the full name of this clinical trial?
IIT2023-14-Zumsteg-ULTRA-HPV: Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer